O priebehu kliešťovej encefalitídy (KE) v gravidite, ako aj o riziku vertikálneho prenosu je v literatúre len veľmi málo informácií. V prá- ci predkladáme kazuistiku pacientky, ktorá ochorela na KE v 37. týždni gravidity alimentárnou cestou. Ochorenie u nej prebehlo pod obrazom meningitídy, bez neurologického poškodenia. Tri týždne po vypuknutí ochorenia porodila zdravé dieťa, ktoré vo veku 2 a pol roka malo negatívny výsledok protilátok proti KE obidvoch tried IgM aj IgG a počas celého obdobia sledovania u neho neboli zazna- menané žiadne známky neurologického poškodenia, či narušený psychomotorický vývin.
There is a lack of information in the literature about the course and risk of vertical transmission of tick-borne encephalitis (TBE) during pregnancy. Presented is a case report of a female patient in the 37 th week of pregnancy infected by foodborne transmission. She developed meningitis with no neurological damage. Three weeks after the first symptoms, she gave birth to a healthy child who, at the age of 30 months, had a negative result of anti-TBE antibodies in both IgM and IgG classes. In the child, no signs of neurolo- gical injury or impaired psychomotor development were observed throughout the follow-up period.
- MeSH
- dospělí MeSH
- infekční komplikace v těhotenství * MeSH
- klíšťová encefalitida diagnóza terapie MeSH
- komplikace těhotenství MeSH
- lidé MeSH
- meningoencefalitida * diagnóza terapie MeSH
- porod MeSH
- těhotenství MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- kazuistiky MeSH
OBJECTIVE: Clostridium difficile infection (CDI) has become one of the most common causes of hospital-acquired infections. Fidaxomicin is one of the latest antibiotics used in the treatment of CDI, however, treatment cost affects recommendations for its use in several countries. We have analysed the treatment of our patients with CDI, treated by fidaxomicin since it was introduced to the market in 2018 and became available in the second biggest Slovak hospital, University Hospital of L. Pasteur. Our aim was to determine efficacy and safety of fidaxomicin in the treatment of CDI in Slovak patients. METHODS: We reviewed all courses of fidaxomicin use in our hospital (n = 60). Fidaxomicin was used for first recurrence (12 times), second recurrence (4 times), third recurrence (2 times), and fifth recurrence (1 patient). 41 patients received fidaxomicin first-line. RESULTS: Success of fidaxomicin treatment was recorded at 86.7% within the whole cohort. In the recurrent Clostridium difficile infection (rCDI) subgroup, fidaxomicin was 63% effective with three patients dying (15.7%) and two patients developing subsequent rCDI. During the duration of the study, 6 patients in total died. Only one of three patients, with three or more recurrences of CDI, had no further presentations after eight weeks of completion of treatment. CONCLUSIONS: The biggest benefit from fidaxomicin treatment was shown in a cohort of patients with primary CDI infection demonstrating a low recurrence rate and significant reduction of fidaxomicin effectiveness in preventing a recurrence when treating patients with multiple rCDI.
- MeSH
- antibakteriální látky terapeutické užití MeSH
- Clostridioides difficile účinky léků izolace a purifikace MeSH
- dítě MeSH
- dospělí MeSH
- fidaxomicin terapeutické užití MeSH
- klostridiové infekce diagnóza farmakoterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Slovenská republika MeSH
